403 related articles for article (PubMed ID: 26074405)
1. Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.
Schmid M; Sammon JD; Reznor G; Kapoor V; Speed JM; Abdollah FA; Sood A; Chun FK; Kibel AS; Menon M; Fisch M; Sun M; Trinh QD
BJU Int; 2016 Aug; 118(2):221-9. PubMed ID: 26074405
[TBL] [Abstract][Full Text] [Related]
2. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
[TBL] [Abstract][Full Text] [Related]
4. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
Keating NL; O'Malley AJ; Smith MR
J Clin Oncol; 2006 Sep; 24(27):4448-56. PubMed ID: 16983113
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
[TBL] [Abstract][Full Text] [Related]
6. Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.
O'Farrell S; Sandström K; Garmo H; Stattin P; Holmberg L; Adolfsson J; Van Hemelrijck M
BJU Int; 2016 Sep; 118(3):391-8. PubMed ID: 26497726
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
8. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.
Keating NL; O'Malley AJ; Freedland SJ; Smith MR
J Natl Cancer Inst; 2010 Jan; 102(1):39-46. PubMed ID: 19996060
[TBL] [Abstract][Full Text] [Related]
9. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
10. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.
Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099
[TBL] [Abstract][Full Text] [Related]
11. Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.
Saylor PJ; Smith MR; O'Malley AJ; Keating NL
Eur Urol; 2014 Mar; 65(3):642-9. PubMed ID: 23428068
[TBL] [Abstract][Full Text] [Related]
12. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
Hu JC; Williams SB; O'Malley AJ; Smith MR; Nguyen PL; Keating NL
Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376
[TBL] [Abstract][Full Text] [Related]
13. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
14. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
Thomsen FB; Sandin F; Garmo H; Lissbrant IF; Ahlgren G; Van Hemelrijck M; Adolfsson J; Robinson D; Stattin P
Eur Urol; 2017 Dec; 72(6):920-928. PubMed ID: 28711383
[TBL] [Abstract][Full Text] [Related]
15. Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer.
Schmid M; Hanske J; Ravi P; Krishna N; Reznor G; Meyer CP; Fisch M; Noldus J; Nguyen PL; Trinh QD
Int J Urol; 2016 Apr; 23(4):305-11. PubMed ID: 26763083
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.
Albertsen PC; Klotz L; Tombal B; Grady J; Olesen TK; Nilsson J
Eur Urol; 2014 Mar; 65(3):565-73. PubMed ID: 24210090
[TBL] [Abstract][Full Text] [Related]
17. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
18. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
20. Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis.
Liu R; Zhou J; Xia S; Li T
Urol Int; 2020; 104(3-4):214-221. PubMed ID: 31747673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
